Review Article | Published:

Human RAG mutations: biochemistry and clinical implications

Nature Reviews Immunology volume 16, pages 234246 (2016) | Download Citation

Abstract

The recombination-activating gene 1 (RAG1) and RAG2 proteins initiate the V(D)J recombination process, which ultimately enables the generation of T cells and B cells with a diversified repertoire of antigen-specific receptors. Mutations of the RAG genes in humans are associated with a broad spectrum of clinical phenotypes, ranging from severe combined immunodeficiency to autoimmunity. Recently, novel insights into the phenotypic diversity of this disease have been provided by resolving the crystal structure of the RAG complex, by developing novel assays to test recombination activity of the mutant RAG proteins and by characterizing the molecular and cellular basis of immune dysregulation in patients with RAG deficiency.

Key points

  • Recombination-activating gene (RAG) mutations in humans are associated with a broad spectrum of clinical phenotypes, ranging from severe, early-onset infections to inflammation and autoimmunity.

  • There is a correlation between the severity of the clinical and immunological phenotypes and the recombination activity of the mutant RAG protein, and hypomorphic mutations that severely affect recombination activity are associated with restriction of the T cell and B cell repertoires. However, environmental factors may also contribute to determining the disease phenotype.

  • Crystal structure and cryo-electron microscopy studies have revealed the structure of the heterotetrameric RAG complex bound to DNA. Fine definition of this structure has also offered important insights into the disease-causing effects of naturally occurring RAG mutations.

  • Studies in patients and in mice have demonstrated that RAG mutations affect central and peripheral T cell and B cell tolerance, including defective expression of autoimmune regulator (AIRE), reduced number and function of regulatory T cells, impaired receptor editing and increased levels of B cell-activating factor (BAFF), allowing the rescue of self-reactive B cells.

  • A broad range of autoantibodies has been demonstrated in patients with RAG mutations presenting with inflammation and autoimmunity. Neutralizing antibodies specific for interferon-α (IFNα) and IFNω have been documented particularly in patients with a history of severe viral infections.

  • Recent data indicate that RAG expression during the early stages of lymphoid development selects cells with improved fitness. NK cells from Rag−/− mice have an activated phenotype and increased cytotoxicity. If confirmed in humans, these data may account for the high rate of graft rejection observed after unconditioned haematopoietic stem cell transplantation in patients with RAG deficiency.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & The V(D)J recombination activating gene, RAG-1. Cell 59, 1035–1048 (1989).

  2. 2.

    , , & RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 248, 1517–1523 (1990).

  3. 3.

    et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869–877 (1992).

  4. 4.

    et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855–867 (1992).

  5. 5.

    et al. RAG mutations in human B cell-negative SCID. Science 274, 97–99 (1996). This is the first study to report that RAG mutations in humans cause SCID.

  6. 6.

    et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell 93, 885–896 (1998). This is the first demonstration that hypomorphic RAG mutations are a cause of Omenn syndrome.

  7. 7.

    et al. Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). J. Clin. Invest. 87, 1352–1359 (1991).

  8. 8.

    et al. Highly restricted human T cell repertoire in peripheral blood and tissue-infiltrating lymphocytes in Omenn's syndrome. J. Clin. Invest. 102, 312–321 (1998).

  9. 9.

    et al. An immunodeficiency disease with RAG mutations and granulomas. N. Engl. J. Med. 358, 2030–2038 (2008). By identifying patients with delayed-onset disease characterized by granulomas and autoimmunity, this manuscript has broadened the spectrum of human RAG deficiency.

  10. 10.

    , , & Crystal structure of the V(D)J recombinase RAG1–RAG2. Nature 518, 507–511 (2015). This study describes the crystal structure of the heterotetrameric complex of RAG1 and RAG2 core domains, offering important insights into RAG complex function and into mechanisms of disease in patients with RAG mutations.

  11. 11.

    & Recruitment of RAG1 and RAG2 to chromatinized DNA during V(D)J recombination. Mol. Cell. Biol. 35, 3701–3713 (2015). This study investigates the specific requirement of RSS substrates with 12–23 spacers for optimal recognition and binding by RAG1.

  12. 12.

    et al. Molecular mechanism of V(D)J recombination from synaptic RAG1-RAG2 complex structures. Cell 163, 1138–1152 (2015). This report shows by cryo-electron microscopy how the RAG complex interacts with RSSs according to the 12–23 rule.

  13. 13.

    , , , & Severe combined immunodeficiencies and related disorders. Nat. Rev. Disease Primers (2015).

  14. 14.

    et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N. Engl. J. Med. 371, 434–446 (2014).

  15. 15.

    et al. A human severe combined immunodeficiency (SCID) condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J. Exp. Med. 188, 627–634 (1998).

  16. 16.

    , & A severe combined immunodeficiency mutation in the mouse. Nature 301, 527–530 (1983).

  17. 17.

    & The scid mutation in mice causes a general defect in DNA repair. Nature 347, 479–482 (1990).

  18. 18.

    , & The clinical impact of deficiency in DNA non-homologous end-joining. DNA Repair (Amst.) 16, 84–96 (2014).

  19. 19.

    Familial reticuloendotheliosis with eosinophilia. N. Engl. J. Med. 273, 427–432 (1965).

  20. 20.

    et al. T helper type 2-like cells and therapeutic effects of interferon-γ in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). Eur. J. Immunol. 23, 56–60 (1993).

  21. 21.

    et al. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur. J. Immunol. 26, 329–334 (1996).

  22. 22.

    et al. Intrathymic restriction and peripheral expansion of the T-cell repertoire in Omenn syndrome. Blood 94, 3468–3478 (1999).

  23. 23.

    et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 97, 81–88 (2001).

  24. 24.

    et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J. Allergy Clin. Immunol. 133, 1092–1098 (2014).

  25. 25.

    et al. A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J. Clin. Invest. 115, 3291–3299 (2005).

  26. 26.

    et al. A variant of SCID with specific immune responses and predominance of γδ T cells. J. Clin. Invest. 115, 3140–3148 (2005).

  27. 27.

    et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 312, 729–738 (2014).

  28. 28.

    & Combined immunodeficiency: the Middle East experience. J. Allergy Clin. Immunol. 131, 658–660 (2013).

  29. 29.

    et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B–severe combined immune deficiency or Omenn syndrome. Blood 97, 2772–2776 (2001).

  30. 30.

    et al. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. J. Allergy Clin. Immunol. 133, 1124–1133 (2014).

  31. 31.

    et al. Evolution of a T-B- SCID into an Omenn syndrome phenotype following parainfluenza 3 virus infection. Clin. Immunol. 115, 70–73 (2005).

  32. 32.

    et al. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency. Blood 106, 2099–2101 (2005).

  33. 33.

    et al. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood 116, 1263–1271 (2010).

  34. 34.

    et al. Highly variable clinical phenotypes of hypomorphic RAG1 mutations. Pediatrics 126, e1248–e1252 (2010).

  35. 35.

    et al. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J. Allergy Clin. Immunol. 132, 969–971 (2013).

  36. 36.

    et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J. Clin. Invest. 125, 4135–4148 (2015). This article reports on the autoantibody repertoire in a large series of patients with RAG mutations, including neutralizing IFNα- and IFNω-specific antibodies in patients with CID–G/AI and a history of severe varicella zoster virus infection.

  37. 37.

    et al. Late-onset combined immune deficiency associated to skin granuloma due to heterozygous compound mutations in RAG1 gene in a 14 years old male. Hum. Immunol. 74, 18–22 (2013).

  38. 38.

    et al. Atypical severe combined immunodeficiency caused by a novel homozygous mutation in Rag1 gene in a girl who presented with pyoderma gangrenosum: a case report and literature review. J. Clin. Immunol. 34, 792–795 (2014).

  39. 39.

    et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J. Allergy Clin. Immunol. 133, 880–882 (2014).

  40. 40.

    et al. Identification of patients with RAG mutations previously diagnosed with common variable immunodeficiency disorders. J. Clin. Immunol. 35, 119–124 (2015).

  41. 41.

    et al. Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations. Blood 117, 5892–5896 (2011).

  42. 42.

    et al. A hypomorphic recombination-activating gene 1 (RAG1) mutation resulting in a phenotype resembling common variable immunodeficiency. J. Allergy Clin. Immunol. 134, 1375–1380 (2014).

  43. 43.

    et al. RAG1 deficiency may present clinically as selective IgA deficiency. J. Clin. Immunol. 35, 280–288 (2015).

  44. 44.

    et al. Leaky RAG deficiency in adult patients with impaired antibody production against bacterial polysaccharide antigens. PLoS ONE 10, e0133220 (2015).

  45. 45.

    et al. A novel homozygous mutation in recombination activating gene 2 in 2 relatives with different clinical phenotypes: Omenn syndrome and hyper-IgM syndrome. J. Allergy Clin. Immunol. 130, 1414–1416 (2012).

  46. 46.

    et al. Exome sequencing reveals RAG1 mutations in a child with autoimmunity and sterile chronic multifocal osteomyelitis evolving into disseminated granulomatous disease. J. Clin. Immunol. 33, 1289–1292 (2013).

  47. 47.

    & Mechanisms controlling expression of the RAG locus during lymphocyte development. Curr. Opin. Immunol. 21, 173–178 (2009).

  48. 48.

    , & Mutational analysis of RAG1 and RAG2 identifies three catalytic amino acids in RAG1 critical for both cleavage steps of V(D)J recombination. Genes Dev. 13, 3059–3069 (1999).

  49. 49.

    , , , & Mutations of acidic residues in RAG1 define the active site of the V(D)J recombinase. Genes Dev. 13, 3070–3080 (1999).

  50. 50.

    , , , & Crystal structure of the RAG1 dimerization domain reveals multiple zinc-binding motifs including a novel zinc binuclear cluster. Nat. Struct. Biol. 4, 586–591 (1997).

  51. 51.

    et al. RAG2 PHD finger couples histone H3 lysine 4 trimethylation with V(D)J recombination. Nature 450, 1106–1110 (2007).

  52. 52.

    , & RAG-1 interacts with the repeated amino acid motif of the human homologue of the yeast protein SRP1. Proc. Natl Acad. Sci. USA 91, 7633–7637 (1994).

  53. 53.

    , & RAG1-mediated ubiquitylation of histone H3 is required for chromosomal V(D)J recombination. Cell Res. 25, 181–192 (2015).

  54. 54.

    , , , & A plant homeodomain in RAG-2 that binds hypermethylated lysine 4 of histone H3 is necessary for efficient antigen-receptor-gene rearrangement. Immunity 27, 561–571 (2007).

  55. 55.

    , & H3K4me3 stimulates the V(D)J RAG complex for both nicking and hairpinning in trans in addition to tethering in cis: implications for translocations. Mol. Cell 34, 535–544 (2009).

  56. 56.

    et al. Ubiquitylation of RAG-2 by Skp2-SCF links destruction of the V(D)J recombinase to the cell cycle. Mol. Cell 18, 699–709 (2005).

  57. 57.

    & Regulation of DNA repair throughout the cell cycle. Nat. Rev. Mol. Cell Biol. 9, 297–308 (2008).

  58. 58.

    et al. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J. Allergy Clin. Immunol. 133, 1099–1108 (2014). This comprehensive analysis of expression and recombination activity of naturally occurring human RAG1 mutant proteins reveals a genotype–phenotype correlation in this disease.

  59. 59.

    , & C-terminal region of RAG1 contacts the coding DNA during V(D)J recombination. Mol. Cell. Biol. 21, 2038–2047 (2001).

  60. 60.

    , & RAG1 mutation found in Omenn syndrome causes coding flank hypersensitivity: a novel mechanism for antigen receptor repertoire restriction. J. Immunol. 181, 4124–4130 (2008).

  61. 61.

    et al. N-terminal RAG1 frameshift mutations in Omenn's syndrome: internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains. Proc. Natl Acad. Sci. USA 97, 14572–14577 (2000).

  62. 62.

    , , & Biochemical and folding defects in a RAG1 variant associated with Omenn syndrome. J. Immunol. 179, 8332–8340 (2007).

  63. 63.

    et al. Analysis of mutations from SCID and Omenn syndrome patients reveals the central role of the Rag2 PHD domain in regulating V(D)J recombination. J. Clin. Invest. 120, 1337–1344 (2010). This study reveals the crucial regulatory role of the non-core PHD region of RAG2 by showing that mutations in the PHD compromise recombination activity by affecting protein stability, nuclear localization and/or interaction with histones.

  64. 64.

    et al. The human gene damage index as a gene-level approach to prioritizing exome variants. Proc. Natl Acad. Sci. USA 112, 13615–13620 (2015).

  65. 65.

    et al. The immunophenotypic and immunogenotypic B-cell differentiation arrest in bone marrow of RAG-deficient SCID patients corresponds to residual recombination activities of mutated RAG proteins. Blood 100, 2145–2152 (2002).

  66. 66.

    et al. Human syndromes of immunodeficiency and dysregulation are characterized by distinct defects in T-cell receptor repertoire development. J. Allergy Clin. Immunol. 133, 1109–1115 (2014).

  67. 67.

    et al. Immature B cells preferentially switch to IgE with increased direct Sμ to Sɛ recombination. J. Exp. Med. 208, 2733–2746 (2011).

  68. 68.

    et al. Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome. J. Exp. Med. 207, 1525–1540 (2010).

  69. 69.

    et al. Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. J. Exp. Med. 207, 1541–1554 (2010). References 68 and 69 demonstrate in animal models and in patients that hypomorphic RAG mutations are associated with abnormalities of central and peripheral B cell tolerance, resulting in the expansion of autoantibody-secreting cell populations.

  70. 70.

    et al. Projection of an immunological self shadow within the thymus by the Aire protein. Science 298, 1395–1401 (2002).

  71. 71.

    et al. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 436, 1181–1185 (2005).

  72. 72.

    , , , & Positive and negative regulatory mechanisms for fine-tuning cellularity and functions of medullary thymic epithelial cells. Front. Immunol. 6, 461 (2015).

  73. 73.

    et al. AIRE deficiency in thymus of 2 patients with Omenn syndrome. J. Clin. Invest. 115, 728–732 (2005). This is the first demonstration that RAG mutations in humans compromise thymic architecture and expression of AIRE and AIRE-dependent TRAs.

  74. 74.

    et al. Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome. Blood 114, 105–108 (2009).

  75. 75.

    et al. Abnormalities of thymic stroma may contribute to immune dysregulation in murine models of leaky severe combined immunodeficiency. Front. Immunol. 2, 15 (2011).

  76. 76.

    et al. Anti-CD3ɛ mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications. Blood 120, 1005–1014 (2012).

  77. 77.

    et al. A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J. Clin. Invest. 117, 1260–1269 (2007).

  78. 78.

    et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3, e289 (2006).

  79. 79.

    et al. Defect of regulatory T cells in patients with Omenn syndrome. J. Allergy Clin. Immunol. 125, 209–216 (2010).

  80. 80.

    et al. Lack of iNKT cells in patients with combined immune deficiency due to hypomorphic RAG mutations. Blood 111, 271–274 (2008).

  81. 81.

    , , , & RAGs and regulation of autoantibodies. Annu. Rev. Immunol. 22, 485–501 (2004).

  82. 82.

    et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20, 441–453 (2004).

  83. 83.

    et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785–798 (2004).

  84. 84.

    et al. B lineage-specific regulation of V(D)J recombinase activity is established in common lymphoid progenitors. J. Exp. Med. 199, 491–502 (2004).

  85. 85.

    et al. The ontogeny and fate of NK cells marked by permanent DNA rearrangements. J. Immunol. 180, 1432–1441 (2008).

  86. 86.

    , & The RAG recombinase dictates functional heterogeneity and cellular fitness in natural killer cells. Cell 159, 94–107 (2014). This study demonstrates that RAG expression during the early stages of lymphoid development allows selection of cells with higher fitness and improved ability to respond to infections and cellular stress.

  87. 87.

    et al. SCID patients with ARTEMIS versus RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood 123, 281–289 (2014).

  88. 88.

    Hacein- et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355–364 (2010).

  89. 89.

    Hacein- et al. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N. Engl. J. Med. 371, 1407–1417 (2014).

  90. 90.

    et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 447–458 (2009).

  91. 91.

    et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120, 3635–3646 (2012).

  92. 92.

    et al. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer. Leukemia 25, 1471–1483 (2011).

  93. 93.

    et al. Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity. Blood 107, 63–72 (2006).

  94. 94.

    et al. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome. J. Allergy Clin. Immunol. 133, 1116–1123 (2014).

  95. 95.

    et al. Gene therapy of RAG-2−/− mice: sustained correction of the immunodeficiency. Blood 100, 3942–3949 (2002).

  96. 96.

    et al. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. Mol. Ther. 20, 1968–1980 (2012).

  97. 97.

    , & Many levels of control of V gene rearrangement frequency. Immunol. Rev. 200, 44–56 (2004).

  98. 98.

    et al. RAG represents a widespread threat to the lymphocyte genome. Cell 162, 751–765 (2015). This study demonstrates that RAG1 associates with chromatin at a very large number of promoters and enhancers in developing lymphocytes. During evolution, protection from illegitimate DNA cleavage and genomic instability has been accomplished by reducing the number of cryptic RSS heptamer sequences near RAG1-binding sites that are not associated with TCR and immunoglobulin genes.

  99. 99.

    , , & Extrachromosomal DNA substrates in pre-B cells undergo inversion or deletion at immunoglobulin V-(D)-J joining signals. Cell 19, 775–783 (1987).

  100. 100.

    & Unequal signal and coding joint formation in human V(D)J recombination. Mol. Cell. Biol. 13, 3900–3906 (1987).

  101. 101.

    et al. The “dispensable” portion of RAG2 is necessary for efficient V-to-DJ rearrangement during B and T cell development. Immunity 17, 639–651 (2002).

  102. 102.

    et al. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. Nature 442, 466–470 (2006).

  103. 103.

    et al. Intestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects. J. Exp. Med. 213, 355–375 (2016).

Download references

Acknowledgements

L.D.N. was supported by grants from the National Institute of Allergy and Infectious Diseases, US National Institutes of Health (NIH; 5R01AI100887) and the March of Dimes (1-FY13-500). J.E.W. was supported by the NIH grant 5K08AI103035.

Author information

Affiliations

  1. Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

    • Luigi D. Notarangelo
    • , Jolan E. Walter
    •  & Yu Nee Lee
  2. Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, Maryland 20892, USA.

    • Min-Sung Kim
  3. Pediatric Allergy and Immunology, and the Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

    • Jolan E. Walter

Authors

  1. Search for Luigi D. Notarangelo in:

  2. Search for Min-Sung Kim in:

  3. Search for Jolan E. Walter in:

  4. Search for Yu Nee Lee in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Luigi D. Notarangelo.

Supplementary information

PDF files

  1. 1.

    Supplementary information S1 (table)

    Missense RAG1 and RAG2 mutations: protein expression, recombination activity, structural effects and in vivo clinical phenotype

Glossary

Non-homologous end joining pathway

(NHEJ pathway). An error-prone pathway that mediates joining of DNA double-strand breaks without requiring a homologous template. In mammals, the NHEJ pathway involves several proteins — Ku70, Ku80, DNA-dependent protein kinase catalytic subunit (DNA-PKcs), Artemis, Cernunnos (also known as XLF and NHEJ1), X-ray repair cross-complementing protein 4 (XRCC4) and DNA ligase IV. Genetic defects of Artemis are the most common cause of radiosensitive severe combined immunodeficiency (SCID) in humans.

Haematopoietic stem cell transplantation

(HSCT). A therapeutic procedure that involves transfusion of donor HSCs into a recipient. HLA matching between the recipient and the donor determines compatibility. HSCT from a haploidentical donor (such as a parent) is associated with a high risk of graft-versus-host disease, unless T cells are depleted. Chemotherapy is often used before HSCT to eliminate the recipient's blood cells and favour engraftment of donor-derived HSCs but is not strictly necessary in infants with severe combined immunodeficiency (SCID).

Cellular radiosensitivity

Susceptibility of cells to the damaging effects of ionizing radiation, resulting in genomic instability, tumour development or cell death. Genetic defects that affect mechanisms of repair of DNA double-strand breaks are associated with increased cellular radiosensitivity.

SCID mouse

An animal model of severe combined immunodeficiency (SCID) that is characterized by lack of T cells and B cells, and increased cellular radiosensitivity. The SCID mouse carries mutations of the Prkdc gene, encoding DNA-dependent protein kinase catalytic subunit (DNA-PKcs).

Purifying selection

In population genetics, purifying selection refers to the selective removal of deleterious alleles from a given population. Purging of these genetic variants occurs when they cause early death or affect the reproductive fitness of affected individuals.

CDR3 spectratyping

(Complementarity-determining region 3 spectratyping). A PCR-based method that measures the diversity of T cell and B cell repertoires, based on the length of the CDR3 of immunoglobulin and T cell receptor transcripts. A Gaussian distribution of CDR3 length is detected in polyclonal T cells and B cells, whereas a single peak is observed in patients with leukaemia or lymphoma, and an altered distribution may be detected in patients with infections, autoimmune diseases or severe impairment of T cell and/or B cell development.

Autoimmune polyendocrinopathy candidiasis and ectodermal dystrophy

(APECED). A monogenic autoimmune disease caused by mutations of the autoimmune regulator (AIRE) gene, affecting central T cell tolerance. Common manifestations of this disease include autoimmune hypoparathyroidism, Addison disease, type 1 diabetes, candidiasis, alopecia and nail dystrophy.

Codon-optimized

Transgenic products that are generated through a process replacing the original codons with synonymous codons for which a more abundant tRNA is available. This facilitates the rate of translation and ultimately results in the production of higher amounts of the protein.

Whole-exome sequencing

A process by which all exons contained in the genome (collectively comprising the exome) are amplified and subjected to high-throughput sequencing. DNA genetic variants that are present in a given individual are identified by comparing the exome of that subject to the normal reference sequence.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nri.2016.28

Further reading